CoChat

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

Open access
Wang, Yitian, Yu, Wei, Zhu, Jian, Wang, Junjie, Xia, Kaishun, Liang, Chengzhen, Tao, Huimin · 2019 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. In this study, human osteosarcoma cell lines were prepared, flow cytometry using antibodies against CD166 was performed on different cell samples. CD166-specific T cells were obtained by viral gene transfer of corresponding DNA plasmids and selectively expanded using IL-2 and IL-15. The ability of CD166.BBζ CAR-T cells to kill CD166 + osteosarcoma cells was evaluated in vitro and in vivo. CD166 was selectively expressed on four different human osteosarcoma cell lines, indicating its role as the novel target for CAR-T cell therapy. CD166.BBζ CAR-T cells killed osteosarcoma cell lines in vitro; the cytotoxicity correlated with the level of CD166 expression on the tumor cells. Intravenous injection of CD166.BBζ CAR-T cells into mice resulted in the regression of the tumor with no obvious toxicity. Together, the data suggest that CD166.BBζ CAR-T cells may serve as a new therapeutic strategy in the future clinical practice for the treatment of osteosarcoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-019-1147-6

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Expression of CD166 antigen on human osteosarcoma cell lines. a. The expression of CD166 on four human osteosarcoma cell lines was evaluated by FACS analysis. Saos-2, MG63 cell lines exhibited CD166 expression at high levels, MNNG/HOS, U2OS cell lines exhibited CD166 expression at low levels, respectively (red histograms). For NIH/3 T3 cell lines, CD166 was undetectable. A CD166 isotype antibody was used as a negative control for the detection of CD166 expression (blue histograms). b. The histogram of GD2 expression on NIH/3 T3 and human osteosarcoma cell lines
Fig. 1 Expression of CD166 antigen on human osteosarcoma cell lines. a. The expression of CD166 on four human osteosarcoma cell lines was evaluated by FACS analysis. Saos-2, MG63 cell lines exhibited CD166 expression at high levels, MNNG/HOS, U2OS cell lines exhibited CD166 expression at low levels, respectively (red histograms). For NIH/3 T3 cell lines, CD166 was undetectable. A CD166 isotype antibody was used as a negative control for the detection of CD166 expression (blue histograms). b. The histogram of GD2 expression on NIH/3 T3 and human osteosarcoma cell linesCC BY · PubMed Central
Fig. 2 Generation of CD166-CART cells in vitro. a. Schematic representation of CD166-based CAR constructs containing the CD3ζ cytosolic domain in combination with the CD137 costimulatory module (CD166.BBζ CAR). VL: variable L chain, L linker, VH: variable H chain, and TM: transmembrane region. b. A representative of CD166-CARs expression on human T cells transduced with lentivirus was analyzed using flow cytometry, which detected GFP expression at day 7 and 14. c. The expression of CD166-CARs in CD4+ and CD8+ T lymphocytes of non-transduced T cell group and CD166-CART group after the transduction. d. The expansion of different T cells in vitro from day 0 to day 21. Results represent mean ± SD of three individual experiments
Fig. 2 Generation of CD166-CART cells in vitro. a. Schematic representation of CD166-based CAR constructs containing the CD3ζ cytosolic domain in combination with the CD137 costimulatory module (CD166.BBζ CAR). VL: variable L chain, L linker, VH: variable H chain, and TM: transmembrane region. b. A representative of CD166-CARs expression on human T cells transduced with lentivirus was analyzed using flow cytometry, which detected GFP expression at day 7 and 14. c. The expression of CD166-CARs in CD4+ and CD8+ T lymphocytes of non-transduced T cell group and CD166-CART group after the transduction. d. The expansion of different T cells in vitro from day 0 to day 21. Results represent mean ± SD of three individual experimentsCC BY · PubMed Central
Fig. 3 Phenotypic analysis of CD166.BBζ CAR-T cells in vitro. a. Flow cytometry comparison of the common surface phenotypes of CD166.BBζ CAR-T cells (red line) at day 14 of culture with freshly isolated T cells (blue line). Histogram overlays show 6 markers related to lymphocyte activation, differentiation, migration, adhesion, and exhaustion. b. Central memory T phenotypes of CD166.BBζ CAR-T cells and non-transduced T cells were evaluated by flow cytometry
Fig. 3 Phenotypic analysis of CD166.BBζ CAR-T cells in vitro. a. Flow cytometry comparison of the common surface phenotypes of CD166.BBζ CAR-T cells (red line) at day 14 of culture with freshly isolated T cells (blue line). Histogram overlays show 6 markers related to lymphocyte activation, differentiation, migration, adhesion, and exhaustion. b. Central memory T phenotypes of CD166.BBζ CAR-T cells and non-transduced T cells were evaluated by flow cytometryCC BY · PubMed Central
Fig. 4 Functional analysis of CD166.BBζ CAR-T cells in vitro. a. Cytotoxic activity of CD166.BBζ CAR-T cells. We used the LDH release assay to evaluate the cytotoxic activity of CD166.BBζ CAR-T cells and non-transduced T cells at different E/T ratios (effector/ target cells). b. Th1/ Th2 cytokine release of CD166.BBζ CAR-T cells. Culture supernatant was collected 24 h later, and the production of IL-2, TNF-α, IFN-γ, IL-4, IL-6, IL-10 were measured using a CBA assay. The results are presented as the mean ± SD from experiments that were performed in triplicate (*P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001)
Fig. 4 Functional analysis of CD166.BBζ CAR-T cells in vitro. a. Cytotoxic activity of CD166.BBζ CAR-T cells. We used the LDH release assay to evaluate the cytotoxic activity of CD166.BBζ CAR-T cells and non-transduced T cells at different E/T ratios (effector/ target cells). b. Th1/ Th2 cytokine release of CD166.BBζ CAR-T cells. Culture supernatant was collected 24 h later, and the production of IL-2, TNF-α, IFN-γ, IL-4, IL-6, IL-10 were measured using a CBA assay. The results are presented as the mean ± SD from experiments that were performed in triplicate (*P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001)CC BY · PubMed Central
Fig. 5 Tumor targeting ability of CD166.BBζ CAR-T cells was evaluated. Intratumoral T cells were detected by immunohistochemical assays (a, b) (shown in brown) and immunofluorescence (c, d) (shown in red), scale bar, 200 μm. The results are presented as the mean ± SD from experiments that were performed in triplicate (*P < 0.05, **P < 0.01)
Fig. 5 Tumor targeting ability of CD166.BBζ CAR-T cells was evaluated. Intratumoral T cells were detected by immunohistochemical assays (a, b) (shown in brown) and immunofluorescence (c, d) (shown in red), scale bar, 200 μm. The results are presented as the mean ± SD from experiments that were performed in triplicate (*P < 0.05, **P < 0.01)CC BY · PubMed Central
Fig. 6 In vivo effects of human CD166.BBζ CAR-T cells on the inhibition of osteosarcoma cell xenografts. a. NOD/SCID mice were injected with Saos-2-fLuc cells for xenograft growth in mice and then injected with CD166.BBζ CAR-T, PBS (with the same volume) or non-transduced T cells i.v. on day 7, 14 and 21. IVIS imaging system was used to measure tumor growth. b. Bioluminescence intensities of osteosarcoma after adoptive T cell therapy were recorded. c. Osteosarcoma tumor weights from the mice treated in different groups at the end of the experiment. Results represent mean ± SD. *P < 0.05 and **P < 0.01 with T-test
Fig. 6 In vivo effects of human CD166.BBζ CAR-T cells on the inhibition of osteosarcoma cell xenografts. a. NOD/SCID mice were injected with Saos-2-fLuc cells for xenograft growth in mice and then injected with CD166.BBζ CAR-T, PBS (with the same volume) or non-transduced T cells i.v. on day 7, 14 and 21. IVIS imaging system was used to measure tumor growth. b. Bioluminescence intensities of osteosarcoma after adoptive T cell therapy were recorded. c. Osteosarcoma tumor weights from the mice treated in different groups at the end of the experiment. Results represent mean ± SD. *P < 0.05 and **P < 0.01 with T-testCC BY · PubMed Central
Fig. 7 Safety evaluation of CAR-T therapy. a. H&E staining shows that there is no obvious off-target toxicity against mouse major organs. × 100 magnifications. Scale bar, 200 μm. b. CD166.BBζ CAR-T cells show no cytolytic activity against healthy HL-7702 cells. hFOB 1.19 and HFL1 cell lines are sensitive to CD166.BBζ CAR-T cells in vitro
Fig. 7 Safety evaluation of CAR-T therapy. a. H&E staining shows that there is no obvious off-target toxicity against mouse major organs. × 100 magnifications. Scale bar, 200 μm. b. CD166.BBζ CAR-T cells show no cytolytic activity against healthy HL-7702 cells. hFOB 1.19 and HFL1 cell lines are sensitive to CD166.BBζ CAR-T cells in vitroCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 79

Metadata

Authors
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H.
Affiliations
Second Affiliated Hospital of Zhejiang University (CN)
Corresponding author
Tao, Huimin
Venue
Journal of Experimental & Clinical Cancer Research
Published
2019-04-17
Volume
38
Issue
1
Pages
168-168
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W2946233185
Cited by
75
References
50
Citations by year
2026: 6 · 2025: 5 · 2024: 11 · 2023: 15 · 2022: 14 · 2021: 10 · 2020: 9 · 2019: 5
FWCI
3.97
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81472504)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
osteosarcoma, chimeric antigen receptor T cells, CD166, 4-1BB, CAR T-cell therapy, solid tumor immunotherapy, tumor cell killing, tumor regression, viral gene delivery
MeSH terms
Receptors, Chimeric Antigen, Animals, Fetal Proteins, Flow Cytometry, Humans, Interleukin-2, Receptors, Antigen, T-Cell, Osteosarcoma, T-Lymphocytes, Signal Transduction, Antigens, CD, Cell Adhesion Molecules, Neuronal, Gene Expression Regulation, Neoplastic, Immunotherapy, Adoptive, Interleukin-15, Activated-Leukocyte Cell Adhesion Molecule, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, 4-1BB Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. https://app.cochat.ai/papers/10.1186/s13046-019-1147-6
The paper
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019). Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-019-1147-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.